"HIV Antibodies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies reactive with HIV ANTIGENS.
- HIV Antibodies
- Antibodies, HIV
- HIV Associated Antibodies
- Antibodies, HIV Associated
- HIV-Associated Antibodies
- Antibodies, HIV-Associated
- HTLV III Antibodies
- Antibodies, HTLV III
- HTLV III LAV Antibodies
- T-Lymphotropic Virus Type III Antibodies, Human
- HTLV-III-LAV Antibodies
- Antibodies, HTLV-III-LAV
- LAV Antibodies
- Antibodies, LAV
- Lymphadenopathy Associated Antibodies
- Antibodies, Lymphadenopathy Associated
- Lymphadenopathy-Associated Antibodies
- Antibodies, Lymphadenopathy-Associated
- T Lymphotropic Virus Type III Antibodies, Human
- AIDS Antibodies
- Antibodies, AIDS
- HTLV-III Antibodies
- Antibodies, HTLV-III
Below are MeSH descriptors whose meaning is more general than "HIV Antibodies".
Below are MeSH descriptors whose meaning is more specific than "HIV Antibodies".
This graph shows the total number of publications written about "HIV Antibodies" by people in this website by year, and whether "HIV Antibodies" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "HIV Antibodies" by people in Profiles.
Diagnosing Acute HIV Infection. Pediatr Ann. 2017 Feb 01; 46(2):e47-e50.
Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. PLoS Pathog. 2016 08; 12(8):e1005815.
Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies. Glycobiology. 2016 Mar; 26(3):251-60.
Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV. Vaccine. 2012 Jan 11; 30(3):607-13.
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010 Sep 30; 467(7315):591-5.
Mucosal HIV-binding antibody and neutralizing activity in high-risk HIV-uninfected female participants in a trial of HIV-vaccine efficacy. J Infect Dis. 2007 Dec 01; 196(11):1637-44.
HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS. 2006 Jul 13; 20(11):1481-9.
Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J Infect Dis. 2005 Dec 15; 192(12):2129-33.
Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999). J Acquir Immune Defic Syndr. 2001 May 01; 27(1):71-8.
CD8+ T-cell-mediated suppression of HIV replication in the first year of life: association with lower viral load and favorable early survival. AIDS. 1997 Jan; 11(1):F9-13.